Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
90Y Ibritumomab tiuxetan · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| 90Y Ibritumomab tiuxetan | DRUG | - |
Inclusion Criteria:Inclusion Criteria -- Step 1 4.1 Histologically proven, recurrent or refractory, CD20+ B-cell NHL reviewed at SUMC. 4.11 The definition of recurrent disease is: previous partial response (PR) or complete response (CR) to treatment followed by disease progression. 4.12 The defin...
90-Y-ibritumomab tiuxetan is used for the treatment of lymphoma, including non-Hodgkin's lymphoma. It is a monoclonal antibody being developed by Biogen Inc. for oncology indications. The drug is currently in clinical development and has been studied in patients with relapsed or refractory non-Hodgkin's lymphoma.
90-Y-ibritumomab tiuxetan is a monoclonal antibody that targets CD20, a protein found on the surface of B-cells. By binding to CD20, the drug delivers a radioactive isotope, yttrium-90, directly to cancer cells, which helps to destroy them. This targeted approach is designed to treat lymphoma while minimizing damage to healthy cells.
90-Y-ibritumomab tiuxetan is developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is responsible for the clinical development and manufacturing of this investigational monoclonal antibody for the treatment of lymphoma.
90-Y-ibritumomab tiuxetan is in Phase 2 clinical development. It has completed one Phase 2 trial and one Phase 1 trial. The drug is investigational and has not been approved by the FDA. It is still being studied to evaluate its safety and efficacy in patients with lymphoma.
90-Y-ibritumomab tiuxetan has been studied in two completed clinical trials. NCT00005592 was a Phase 2 trial in patients with relapsed or refractory non-Hodgkin's lymphoma. NCT00186589 was a Phase 1 trial combining the drug with high-dose chemotherapy and autologous transplantation for relapsed or resistant non-Hodgkin's lymphoma.
90-Y-ibritumomab tiuxetan is a radiolabeled form of ibritumomab tiuxetan, where the antibody is conjugated to the radioactive isotope yttrium-90. This form is specifically designed for radioimmunotherapy, delivering radiation directly to cancer cells. It is being studied for the treatment of lymphoma.